114 related articles for article (PubMed ID: 7367966)
21. [Electrophysiological parameters of the organ of vision in patients with breast cancer and lymphogranulomatosis receiving antineoplastic chemotherapy].
Gadzhieva NR
Vestn Oftalmol; 2003; 119(2):41-3. PubMed ID: 13678011
[TBL] [Abstract][Full Text] [Related]
22. [Cytostatic chemotherapy of lymphogranulomatosis].
Cohnen G
Med Monatsschr; 1976 Apr; 30(4):160-4. PubMed ID: 958143
[No Abstract] [Full Text] [Related]
23. [Prognosis of lymphogranulomatosis].
Kob D; Kob G
Dtsch Gesundheitsw; 1971 Oct; 26(42):1980-5. PubMed ID: 5144065
[No Abstract] [Full Text] [Related]
24. [Hodgkin's disease. Apropos of a case with cerebral localization].
Jacquillat C; Khayat D; Gautier JC; Pertuiset B
Nouv Presse Med; 1981 Sep; 10(34):2828-9. PubMed ID: 7312595
[No Abstract] [Full Text] [Related]
25. [Combination chemotherapy with total or subtotal lymphatic irradiation in the treatment of lymphogranulomatosis, stage IIIA or IIIB (based on five- and ten-year results)].
Kanaev SV; Gershanovich ML; Malinin AP
Vopr Onkol; 1997; 43(1):32-8. PubMed ID: 9133084
[TBL] [Abstract][Full Text] [Related]
26. Rituximab in lymphocyte-predominant Hodgkin disease.
Azim HA; Pruneri G; Cocorocchio E; Cinieri S; Raviele PR; Bassi S; Preda L; Martinelli G; Peccatori FA
Oncology; 2009; 76(1):26-9. PubMed ID: 19033694
[TBL] [Abstract][Full Text] [Related]
27. [Treatment of Hodgkin disease].
Teillet F; Miot C; Bayle-Weisgerber C; Clot P; Lemercier N
Soins; 1981 May; 26(9):13-9. PubMed ID: 6910824
[No Abstract] [Full Text] [Related]
28. [Chemotherapy of MOPP and C-MOPP resistant cases of malignant lymphoma. (A preliminary report) (author's transl)].
Kolarić K; Tomek R; Roth A
Lijec Vjesn; 1980 Jun; 102(6):306-9. PubMed ID: 7453477
[No Abstract] [Full Text] [Related]
29. [A comparison of two risk-adapted regimens of therapy for Hodgkin's disease in children and adolescents].
Kuleva SA; Anishkin MIu; Kolygin BA
Vopr Onkol; 2008; 54(1):53-8. PubMed ID: 18416058
[TBL] [Abstract][Full Text] [Related]
30. [Lymphogranulomatosis from the surgical viewpoint].
Foramitti FX; Jenny H
Wien Klin Wochenschr; 1968 Jun; 80(24):478-81. PubMed ID: 4175984
[No Abstract] [Full Text] [Related]
31. Laboratory examinations in patients suffering from generalized lymphogranulomatosis and tumorous reticulosis treated with Vinblastin with special regard to evaluation of the efficiency and toxicity of the drug.
Neustadt VN
Ther Hung; 1969; 17(2):67-70. PubMed ID: 5807610
[No Abstract] [Full Text] [Related]
32. [Importance of nucleolar lymphocyte changes during a course of malignant lympho-granuloma].
Dienstbier Z; Vĕtrovcová-Wienerová E; Foltýnová V
Cas Lek Cesk; 1976 Feb; 115(8):246-50. PubMed ID: 1253234
[No Abstract] [Full Text] [Related]
33. [The functional status of the cardiovascular system in the late period after the combined therapy of patients with lymphogranulomatosis].
Balashov AT; Miasnikov AA; Polezhaev IuN; Kheĭfets LM
Ter Arkh; 1996; 68(12):12-4. PubMed ID: 9054028
[TBL] [Abstract][Full Text] [Related]
34. [Use of nifuron in lymphogranulomatosis].
Krasiukova LI
Probl Gematol Pereliv Krovi; 1969 Feb; 14(2):17-21. PubMed ID: 5351082
[No Abstract] [Full Text] [Related]
35. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma.
De Bruin ML; Dorresteijn LD; van't Veer MB; Krol AD; van der Pal HJ; Kappelle AC; Boogerd W; Aleman BM; van Leeuwen FE
J Natl Cancer Inst; 2009 Jul; 101(13):928-37. PubMed ID: 19535773
[TBL] [Abstract][Full Text] [Related]
36. [Late complications of combined therapy of lymphogranulomatosis].
Miasnikov AA; Balashov AT; Berliner GB; Polezhaev IN
Klin Med (Mosk); 1997; 75(3):21-3. PubMed ID: 9229607
[TBL] [Abstract][Full Text] [Related]
37. [Functional state of the kidneys in patients with lymphogranulomatosis during treatment].
Sarnitskiĭ IP; Temnik IV
Klin Khir (1962); 1979 Mar; (3):34-7. PubMed ID: 439652
[No Abstract] [Full Text] [Related]
38. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
39. [The chemotherapeutic treatment of advanced Hodgkin's disease].
Epelbaum R; Haim N; Ben-Shahar M; Valtuch I; Faraggi D; Sharabi-Nov A; Ben-Arie Y; Cohen Y
Harefuah; 2001 Apr; 140(4):311-5, 367. PubMed ID: 11303395
[TBL] [Abstract][Full Text] [Related]
40. [Long-term results of polychemotherapy for Hodgkin's disease in children].
Kolygin BA
Vopr Onkol; 2003; 49(4):501-4. PubMed ID: 14569946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
